Hepatitis A vaccine. A new convenient single-dose schedule with booster when long-term immunization is warranted

TY - JOUR

T1 - Hepatitis A vaccine. A new convenient single-dose schedule with booster when long-term immunization is warranted

AU - Victor, J

AU - Knudsen, J D

AU - Nielsen, L P

AU - Fomsgaard, A

AU - Thybo, S

AU - Bygbjerg, I

AU - Westh, H

N1 - Keywords: Adolescent; Adult; Hepatitis A Vaccines; Hepatitis A Virus, Human; Hepatitis Antibodies; Humans; Immunization Schedule; Immunization, Secondary; Viral Hepatitis Vaccines

PY - 1994

Y1 - 1994

N2 - A total of 162 anti-HAV-negative healthy adults were immunized with a single high dose (1440 ELISA units = 1 ml) of inactivated hepatitis A vaccine and a booster was given at month 6. Antibodies were measured after modification of a commercial ELISA kit, enabling quantification of titres down to 6 mIU ml-1. After 14 days, 96% of vaccinees had positive anti-HAV titres (> 20 mIU ml-1), and after 30 days all vaccinees had seroconverted. The geometric mean titres were 150 mIU ml-1 and 380 mIU ml-1 respectively. The booster dose at month 6 elicited a dramatic (25-fold) increase in antibody titres from 125 to 3090 mIU ml-1. Thus a single dose may be a convenient alternative to immunoglobulin for inducing rapid seroprotection, with a booster dose at month 6 ensuring long-lasting protection.

AB - A total of 162 anti-HAV-negative healthy adults were immunized with a single high dose (1440 ELISA units = 1 ml) of inactivated hepatitis A vaccine and a booster was given at month 6. Antibodies were measured after modification of a commercial ELISA kit, enabling quantification of titres down to 6 mIU ml-1. After 14 days, 96% of vaccinees had positive anti-HAV titres (> 20 mIU ml-1), and after 30 days all vaccinees had seroconverted. The geometric mean titres were 150 mIU ml-1 and 380 mIU ml-1 respectively. The booster dose at month 6 elicited a dramatic (25-fold) increase in antibody titres from 125 to 3090 mIU ml-1. Thus a single dose may be a convenient alternative to immunoglobulin for inducing rapid seroprotection, with a booster dose at month 6 ensuring long-lasting protection.

M3 - Journal article

C2 - 7856299

SN - 0264-410X

VL - 12

SP - 1327

EP - 1329

JO - Vaccine

JF - Vaccine

IS - 14

ER -